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Objectives: Increasing antimicrobial resistance rates limit empirical antimicrobial treatment options for
Gram-negative bloodstream infections (GN-BSI). However, antimicrobial resistance may be predicted
based on patient-speciﬁc risk factors using precision medicine concepts. This retrospective, 1:2 matched
cohort examined clinical outcomes in hospitalized adults without major risk factors for antimicrobial
resistance receiving empirical ﬂuoroquinolones or broad-spectrum beta-lactams (BSBL) for GN-BSI at
Prisma Health-Midlands hospitals in Columbia, SC, USA from January 2010 through June 2015.
Methods: Multivariable logistic regression was used to examine early treatment failure at 72–96 h from
GN-BSI. Cox proportional hazards regression was used to examine 28-day mortality and hospital length
of stay (HLOS).
Results: Among 74 and 148 patients receiving empirical ﬂuoroquinolones and BSBL for GN-BSI,
respectively, median age was 68 years, 159 (72%) were women, and 152 (68%) had a urinary source of
infection. Early treatment failure rates were comparable in ﬂuoroquinolone and BSBL groups (27% vs.
30%, respectively, odds ratio 0.82, 95% conﬁdence intervals [CI] 0.43–1.54, P = 0.53), as well as 28-day
mortality (8.9% vs. 9.7%, respectively, hazards ratio [HR] 0.74, 95% CI 0.26–1.90, P = 0.54). Median HLOS
was 6.1 days in the ﬂuoroquinolone group and 7.1 days in the BSBL group (HR 0.73, 95% CI 0.54–0.99, P =
0.04). Transition from intravenous to oral therapy occurred sooner in the ﬂuoroquinolone group than in
the BSBL group (3.0 vs. 4.9 days, P < 0.001).
Conclusions: In the absence of antimicrobial resistance risk factors, ﬂuoroquinolones provide an
additional empirical treatment option to BSBL for GN-BSI. Shorter HLOS in the ﬂuoroquinolone group
may be due to earlier transition from intravenous to oral antimicrobial therapy.
© 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Increasing rates of antimicrobial resistance in both community
and healthcare settings limit the utility of ﬂuoroquinolones for
empirical therapy of hospitalized patients with Gram-negative
bloodstream infections (GN-BSI) [1–3]. This leaves many patients
with serious penicillin and cephalosporin allergies without safe
and effective antimicrobial agents for empirical therapy [4]. In
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addition, it also limits early oral antimicrobial switch options in
patients who demonstrate rapid clinical improvement soon after
hospital admission. Recent studies have demonstrated the
feasibility of an intravenous to oral antimicrobial switch strategy
in GN-BSI after 3 days, when conventional in vitro antimicrobial
susceptibility testing results became available [5–8]. However, in
the era of precision medicine, antimicrobial resistance may be
estimated using clinical risk prediction tools based on patientspeciﬁc risk factors for antimicrobial resistance [9–12]. More
speciﬁcally, recent literature has demonstrated <10% resistance
rates to both ﬂuoroquinolones and third-generation cephalosporins in bloodstream isolates of patients without major risk factors
for antimicrobial resistance, such as recent antimicrobial use,
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ambulatory gastrointestinal or genitourinary procedures, or
residence in skilled nursing facilities [11,12].
In this study, it was hypothesized that hospitalized patients
without major risk factors for antimicrobial resistance treated
empirically with ﬂuoroquinolones for GN-BSI had comparable
clinical outcomes to those receiving broad-spectrum beta-lactams
(BSBL). The primary aim of this matched retrospective cohort study
was examination of early treatment failure between 72 and 96 h of
GN-BSI based on empirical antimicrobial therapy. Secondary outcomes included 28-day mortality and hospital length of stay (HLOS).
2. Materials and methods
2.1. Settings
The study was conducted at Prisma Health-Midlands
(previously Palmetto Health) Richland and Baptist Hospitals in
Columbia, South Carolina, USA. These are the two largest hospitals
within Prisma Health-Midlands network in South Carolina. The
local Institutional Review Board approved the study and waived
informed consent.

excluded from the study [11,12]. Among 674 patients without
major risk factors for antimicrobial resistance, 74 received
empirical ﬂuoroquinolone monotherapy, 412 received BSBL
monotherapy, and the remaining 188 were empirically treated
with either combination or other antimicrobial regimens (Fig. 1).
Since treatment allocation was not randomized in this retrospective cohort design, patients receiving ﬂuoroquinolone empirical
therapy were randomly matched to those receiving BSBL in a 1:2
fashion based on age (10 years), sex, and exact bloodstream
infection mortality risk score (BSIMRS). The BSIMRS has been
derived and validated to predict mortality in patients with GN-BSI
and encompasses major comorbidities, source of infection, and
acute severity of illness as per the Pitt bacteremia score [19,20]. The
Pitt bacteremia score was used as a primary measure of acute
severity of illness since it does not include arterial blood gases and
other laboratory variables that may not be obtained in all patients,
particularly those admitted to the general hospital ﬂoors [21]. The
modiﬁed sequential organ failure assessment (mSOFA) was used as
a secondary score of acute severity of illness for reassurance [22].
To avoid enrolling the same patient more than once into the cohort,
patients were removed from the screening pool upon study
enrolment.

2.2. Deﬁnitions
2.4. Statistical analysis
Blood cultures were processed using standard microbiology
techniques according to the Clinical and Laboratory Standards
Institute (CLSI). In vitro antimicrobial susceptibility testing was
performed via the VITEK1 2 system (bioMérieux; Marcy l'Etoile,
France) throughout the study period. The site of infection
acquisition and primary source of GN-BSI were classiﬁed as
previously deﬁned [13,14]. HLOS was deﬁned as time from
collection of index blood culture to discharge from the hospital.
Empirical ﬂuoroquinolone therapy was deﬁned as receipt of
intravenous or oral ﬂuoroquinolones within 24 h of collection of
index blood cultures and continued for at least 48 h. Empirical BSBL
therapy was deﬁned as receipt of intravenous piperacillin/
tazobactam, third- or fourth-generation cephalosporins, carbapenems, or aztreonam, within 24 h of GN-BSI and continued for at
least 48 h. Appropriateness of empirical antimicrobial therapy was
deﬁned based on in vitro antimicrobial susceptibility testing
results, route, and dose of empirical antimicrobial regimen as
previously deﬁned [15]. Early treatment failure was deﬁned as
death within 72 h of GN-BSI or presence of 2 early clinical failure
criteria (ECFC) between 72 and 96 h of GN-BSI [16]. ECFC were
recently proposed as objective criteria to determine response to
empirical antimicrobial therapy based on variables that independently predicted 28-day mortality or prolonged hospitalization for
>14 days. These criteria were assessed between 72 and 96 h of GNBSI and included: systolic blood pressure <100 mmHg or
vasopressor use, heart rate >100 beats/min, respiratory rate 22
breaths/min or mechanical ventilation, altered mental status, and
peripheral white blood cell count >12 000/mm3 [16]. Sepsis was
deﬁned as quick sequential organ failure assessment (qSOFA) score
2 as per sepsis-3 criteria [17]. All study deﬁnitions, variables, and
outcomes were determined a priori.
2.3. Case ascertainment
In this quasi-experimental cohort study, all adult patients with
monomicrobial BSI due to aerobic Gram-negative bacilli from 1
January 2010 to 30 June 2015 were identiﬁed through central
microbiology laboratory databases at Prisma Health-Midlands (n =
1163) as previously described [18]. Patients who had at least one
major risk factor for antimicrobial resistance, such as recent
antimicrobial use, ambulatory gastrointestinal or genitourinary
procedures, or residence in skilled nursing facilities (n = 489), were

The primary objective of the study was to evaluate impact of
empirical antimicrobial therapy on early treatment failure at 72–
96 h of GN-BSI. Secondary objectives were 28-day mortality and
HLOS in patients who received empirical ﬂuoroquinolones and
BSBL.
Since patients in both treatment groups were matched by age,
sex, and BSIMRS, the propensity of receiving empirical ﬂuoroquinolones was determined based on differences in non-matched
variables. In the multivariable logistic regression modelling the
propensity of receiving empirical ﬂuoroquinolones, variables were
included if P-value was <0.10 in the univariable model using
backward selection. Multivariable logistic regression was then
used to examine early treatment failure at 72–96 h of onset of GNBSI after adjustment for the propensity of receiving empirical
ﬂuoroquinolones. Odds ratios (OR) and 95% conﬁdence intervals
(CI) were reported to describe the strength of association between
each variable and early treatment failure.
Kaplan–Meier analysis was used to examine 28-day mortality
in patients receiving empirical ﬂuoroquinolones and BSBL. Patients
were followed from time of index blood culture collection for 28
days or until death. This allowed censoring of patients who were
lost to follow-up before 28 days from GN-BSI. Patients lost to
follow-up were censored at the date of last documented healthcare
visit. Log-rank P-value was used to assess the statistical signiﬁcance of the difference in 28-day mortality between the two
treatment groups. Multivariable Cox proportional hazards regression model was used to compare 28-day mortality between
ﬂuoroquinolone and BSBL groups after adjustment for the
propensity of receiving empirical ﬂuoroquinolones. The proportional hazards assumption was evaluated by plotting the log
integrated hazard vs. time from the Kaplan–Meier method. Hazard
ratios (HR) with 95% CI were reported to indicate the strength of
association between the treatment group and 28-day mortality.
Kaplan–Meier analysis and multivariable Cox proportional
hazards regression were also used to examine HLOS following
GN-BSI after adjustment for the propensity of receiving empirical
ﬂuoroquinolones. Patients were followed from time of collection of
index blood culture until discharge from the hospital. Patients who
died prior to hospital discharge were censored on the date of death
to avoid accounting for early mortality as a favourable outcome.
Log-rank P-value was used to assess the statistical signiﬁcance of
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Fig. 1. Flowchart of case ascertainment in study. BSBL, broad-spectrum beta-lactams; BSIMRS, bloodstream infection mortality risk score; GI, gastrointestinal; GN-BSI, Gramnegative bloodstream infection; GU, genitourinary.

the difference in HLOS between patients who received empirical
ﬂuoroquinolones and BSBL therapy. HR with 95% CI were presented
to demonstrate the strength of association between the treatment
group and HLOS.
JMP Pro (version 13.0, SAS Institute Inc., Cary, NC) was used for
statistical analysis. The level of signiﬁcance for statistical testing
was deﬁned as P < 0.05 (two-sided) unless otherwise speciﬁed.
3. Results
3.1. Clinical characteristics of the cohort
Among patients without major risk factors for antimicrobial
resistance during the study period, 74 receiving empirical
ﬂuoroquinolone monotherapy were matched to 148 who received
BSBL for GN-BSI. Since patients were matched by age, sex, and
BSIMRS, there were no major differences in baseline demographics
or clinical characteristics between the two groups (Table 1). Acute
severity of illness as determined by the Pitt bacteremia score,
mSOFA, and the proportion of patients with sepsis was comparable
between the two groups. Overall, the majority of GN-BSI were
community-acquired, the urinary tract was the most common
source of infection, and Escherichia coli was the most common
bloodstream isolate. In addition, since patients with major risk
factors for antimicrobial resistance were excluded from the
analysis, only eight patients (4%) in this cohort overall received

inappropriate empirical antimicrobial therapy (Table 1). Antimicrobial susceptibility results of bloodstream isolates to commonly
tested BSBL and ﬂuoroquinolones are listed in Table 2. Charlson
comorbidity score was the only variable that differed between the
two treatment groups and was included in the logistic regression
modelling the propensity of receiving empirical ﬂuoroquinolone
therapy.
Levoﬂoxacin (54 patients; 73%) and ciproﬂoxacin (20; 27%)
were the only ﬂuoroquinolones used for empirical therapy of GNBSI. Empirical BSBL included ceftriaxone (57; 39%), piperacillin/
tazobactam (55; 37%), meropenem (17; 11%), cefepime (10; 7%),
ertapenem (5; 3%), and others (4; 3%).
3.2. Clinical outcomes of patients with GN-BSI
Early treatment failure and 28-day mortality rates were
comparable between the two groups (Table 3; Fig. 2). After
adjustments for the propensity of receiving empirical ﬂuoroquinolones in the respective multivariable models, there were no
signiﬁcant differences in early treatment failure (OR 0.82, 95% CI:
0.43–1.54, P = 0.53) or 28-day mortality (HR 0.74, 95% CI: 0.26–1.90,
P = 0.54) in patients who received empirical ﬂuoroquinolones
relative to BSBL (Table 4).
Median HLOS was 6.1 and 7.1 days in the ﬂuoroquinolone and
BSBL groups, respectively (P = 0.04; Fig. 3). This difference
remained statistically signiﬁcant after adjustment for the
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Table 1
Baseline demographics, clinical characteristics, and microbiology of bloodstream infections, based on empirical antimicrobial therapy.
Variable

Fluoroquinolones (n = 74)

BSBL (n = 148)

P-value

Age, median (IQR)
Female, n (%)
BSIMRS, median (IQR)
Cancer, n (%)
Liver cirrhosis, n (%)
High inoculum infection,a n (%)
Pitt bacteremia score, median (IQR)
mSOFA, median (IQR)
Sepsis, n (%)
Charlson comorbidity score, median (IQR)
Site of acquisition, n (%)
Community-acquired
Healthcare-associated
Hospital-acquired
Urinary source of infection, n (%)
Microbiology, n (%)
Escherichia coli
Klebsiella species
Proteus mirabilis
Other Enterobacteriaceae
Lactose non-fermenters
Inadequate source control, n (%)
Inappropriate empirical antimicrobial therapy, n (%)

67 (56–80)
53 (72)
2 (0–4)
10 (14)
3 (4)
23 (31)
1 (1–3)
2 (1–4)
26 (35)
2 (1–3)

68 (55–79)
106 (72)
2 (0–4)
14 (9)
7 (5)
40 (27)
1 (1–3)
2 (1–3)
55 (37)
1 (0–3)

54 (73)
12 (16)
8 (11)
49 (66)

103 (70)
28 (19)
17 (11)
103 (70)

45 (61)
11 (15)
8 (11)
8 (11)
2 (3)
1 (1)
5 (7)

101 (68)
20 (14)
4 (3)
18 (12)
5 (3)
2 (1)
3 (2)

Matched
Matched
Matched
–
–
–
–
0.82
0.77
0.10
0.86
–
–
–
0.61
0.19
–
–
–
–
–
0.99
0.12

BSBL, broad-spectrum beta-lactams; BSIMRS, bloodstream infection mortality risk score; IQR, interquartile range; mSOFA, modiﬁed sequential organ failure assessment.
a
Source of bloodstream infection other than urinary tract or central venous catheter infection.

propensity of receiving empirical ﬂuoroquinolones in the multivariable model (HR 0.73, 95% CI: 0.54–0.99, P = 0.04). Transition
from intravenous to oral antimicrobial therapy occurred earlier in
the ﬂuoroquinolone than the BSBL group (median of 3.0 vs. 4.9
days, P < 0.001). There was no difference in 28-day mortality
between the 37 patients transitioned from intravenous to oral
ﬂuoroquinolones within the ﬁrst 3 days of BSI and the other 37
who remained on intravenous ﬂuoroquinolones during the ﬁrst 3
days of BSI (8.6% vs. 9.2%, log-rank P = 0.93).
4. Discussion
4.1. Impact of empirical antimicrobial therapy on outcomes
To our knowledge, this is the ﬁrst study to compare effectiveness of ﬂuoroquinolones to BSBL for empirical therapy of GN-BSI.
Earlier studies demonstrated that ciproﬂoxacin was non-inferior to
ceftazidime for empirical therapy of serious Gram-negative
infections soon after introduction of the ﬂuoroquinolone class to
the antimicrobial arsenal [23,24]. However, replication of these
results became impractical after the linear increase in ﬂuoroquinolone resistance rates among Gram-negative bloodstream isolates
[1–3]. A recent study suggested clinical beneﬁt of appropriate
empirical ﬂuoroquinolone therapy over third-generation cephalosporins in a retrospective cohort of patients with communityonset BSI due to ﬂuoroquinolone-susceptible Gram-negative
bacilli [25]. However, application of study results in clinical
Table 2
Antimicrobial susceptibility testing results of bloodstream isolates in the two
treatment groups.
Antimicrobial agent

Fluoroquinolones (n = 74)

BSBL (n = 148)

Piperacillin/tazobactam
Ceftazidime
Cefepime
Meropenem
Ciproﬂoxacin

70/72 (97)
72/73 (99)
73 (99)
74 (100)
69 (93)

143/145 (99)
145 (98)
147 (99)
146 (99)
137 (93)

Data represent number of susceptible isolates (percentage of susceptible isolates) if
all isolates were tested; otherwise number of susceptible isolates/number of
isolates tested (percentage of susceptible isolates).
BSBL, broad-spectrum beta-lactams.

practice was dependent on prospective identiﬁcation of patients
with BSI due to ﬂuoroquinolone-susceptible bacteria at the time of
the decision-making regarding empirical antimicrobial therapy.
Recent advancements in clinical tools for prediction of antimicrobial resistance using patient-speciﬁc risk factors allowed precise
estimation of the probability of ﬂuoroquinolone resistance in
Gram-negative bloodstream isolates [9,11]. The current study
included only patients with low predicted risk of antimicrobial
resistance at initial presentation and, predictably, over 90% had BSI
due to ﬂuoroquinolone-susceptible Gram-negative bacilli. The
study results provide an alternative empirical antimicrobial option
to BSBL in patients with GN-BSI who may not be eligible for betalactam therapy. This includes patients who had prior adverse
events to both penicillins and cephalosporins and those with
recent major penicillin allergies such as anaphylaxis or angioedema. In the absence of major risk factors for antimicrobial
resistance, empirical ﬂuoroquinolones had comparable early
treatment failure and 28-day mortality to BSBL.
4.2. Early transition from intravenous to oral antimicrobial therapy
The study also has clinical implications in early transition from
intravenous to oral antimicrobial therapy. Fluoroquinolones
remain the most frequently used oral antimicrobial agents in
patients with GN-BSI. In a recent multicentre cohort and a
randomized clinical trial, 70% and 74% of patients transitioned from
intravenous to oral therapy for Enterobacteriaceae and GN-BSI,
respectively, received oral ﬂuoroquinolones [7,26]. However,
transitioning from intravenous to oral antimicrobial therapy often
occurred after 72 h of GN-BSI to ensure that bloodstream isolates
were susceptible to oral antimicrobial regimen [5–8]. In the
current study, using simple clinical criteria for risk stratiﬁcation of
antimicrobial resistance allowed early transition from intravenous
to oral antimicrobial therapy within 3 days of GN-BSI in one-half of
patients in the ﬂuoroquinolone group. This early and smooth
transition from intravenous to oral therapy likely contributed to
shorter HLOS in the ﬂuoroquinolone group than in the BSBL group.
This was consistent with the results of prior cohort studies that
demonstrated an association between transition from intravenous
to oral antimicrobial therapy and shorter HLOS [6–8]. However, to
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Table 3
Summary of primary and secondary outcomes of patients with Gram-negative bloodstream infections by treatment group.
Outcome

Fluoroquinolones (n = 74)

BSBL (n = 148)

P-value

Early treatment failure, n (%)
Death within 72 h of BSI
ECFC 2 from 72 to 96 h of BSI
Hypotension
Tachycardia
Respiratory failure
Altered mental status
Leucocytosis
28-day mortalitya
Median HLOS in daysa

20 (27)
1 (1)
19 (26)
12 (16)
18 (24)
15 (20)
8 (11)
14 (19)
8.9%
6.1

44 (30)
6 (4)
38 (26)
22 (15)
44 (30)
30 (20)
19 (13)
28 (19)
9.7%
7.1

0.67
–
–
–
–
–
–
–
0.79
0.04

BSBL, broad-spectrum beta-lactams; BSI, bloodstream infection; ECFC, early clinical failure criteria; HLOS, hospital length of stay.
a
Results were obtained from respective Kaplan–Meier curves.

Fig. 2. Mortality in patients with Gram-negative bloodstream infection by empirical antimicrobial therapy. Red line indicates ﬂuoroquinolones and blue line indicates broadspectrum beta-lactams. Log-rank P = 0.79.

Table 4
Univariable and multivariable model results for primary and secondary outcomes of study.
Outcome

Early treatment failure
28-day mortality
Hospital length of stay

Multivariable modela

Univariable model
OR/HR

(95% CI)

P-value

OR/HR

(95% CI)

P-value

0.88
0.88
0.74

(0.50–1.63)
(0.31–2.23)
(0.55–1.00)

0.68
0.79
0.047

0.82
0.74
0.73

(0.43–1.54)
(0.26–1.90)
(0.54–0.99)

0.53
0.54
0.043

OR and HR in patients receiving empirical ﬂuoroquinolones relative to broad-spectrum beta-lactams.
CI, conﬁdence interval; HR, hazards ratio; OR, odds ratio.
a
After adjustment for the propensity of receiving empirical ﬂuoroquinolones based on Charlson comorbidity score.

our knowledge, this is the ﬁrst study to demonstrate feasibility of
intravenous to oral transition of antimicrobial therapy within 3
days of GN-BSI. It was reassuring that early transition from
intravenous to oral ﬂuoroquinolones within 3 days of BSI was not
associated with increased 28-day mortality. This approach requires
healthcare providers to be familiar with local risk factors for
antimicrobial resistance and conﬁdent in estimating the probability of antimicrobial resistance rates using available resources.
Utilization of novel methods for rapid phenotypic antimicrobial
susceptibility testing using morphokinetic cellular analysis provides an arguably more precise, albeit more expensive, alternative

to clinical risk assessment tools for prediction of antimicrobial
resistance [27–29]. Future larger trials examining early transition
from intravenous to oral antimicrobial therapy within 3 days of
GN-BSI would yield valuable results.
4.3. Strengths and limitations
Matching by predicted prognosis using the BSIMRS represents
the major strength of this study as it allows examination of patients
with comparable baseline prognosis prior to initiation of empirical
antimicrobial therapy. The study has the following limitation. First,
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Fig. 3. Hospital length of stay following Gram-negative bloodstream infection by empirical antimicrobial therapy. Red line indicates ﬂuoroquinolones and blue line indicates
broad-spectrum beta-lactams. Log-rank P = 0.04.

it shares common limitations of retrospective cohorts, including
the potential of not accounting for unknown confounders. Second,
the number of patients who received empirical ﬂuoroquinolone
therapy during the study period was relatively small. This is
conceivably because the non-stratiﬁed use of empirical ﬂuoroquinolone therapy for GN-BSI has been discouraged due to
increasing antimicrobial resistance rates. However, the study
had adequate power to examine the primary outcome of early
treatment failure. Third, the study was conducted at two hospitals
within the same healthcare system. The antimicrobial stewardship
and support team provided real-time recommendations regarding
empirical antimicrobial therapy and oral switch options in patients
with GN-BSI. These results may not be generalizable to settings
with limited access to infectious diseases specialists and antimicrobial stewardship expertise in prediction of antimicrobial
resistance.
5. Conclusion
In patients with low predicted risk of antimicrobial resistance,
empirical ﬂuoroquinolone therapy for GN-BSI had comparable
early treatment failure and 28-day mortality to BSBL. Early
transition from intravenous to oral antimicrobial therapy likely
contributed to shorter HLOS in the ﬂuoroquinolone group than in
the BSBL group.
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